Adam Feuerstein

TheStreet.com Senior Columnist

Before joining TheStreet.com in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
« Back
Page 1 of 382
Article

Elan Shares Rise on J&J Investment

By Adam Feuerstein

Elan announces a $1.5 billion investment by J&J wherein it will take over Elan's Alzheimer's unit and assume an 18.4% stake in the company.

11:10AM 07/02/09

Article

Biotech Stock Mailbag: Spectrum Pharmaceuticals

By Adam Feuerstein

Readers weigh in on Spectrum Pharma, Cell Therapeutics and Geron, and force us to explain -- again -- TheStreet's rules on stock ownership.

09:42AM 07/02/09

Article

AMAG's Got Room to Run

By Adam Feuerstein

Upside remains in AMAG stock price even with Feraheme approval.

11:02AM 07/01/09

Article

Acorda (RealMoney.com $)

By Adam Feuerstein

09:28AM 07/01/09

Article

Geron Fans Make Mountain Out of GE Molehill

By Adam Feuerstein

As with most announcements from Geron, investors overreact to news of a stem-cell deal with GE.

12:41PM 06/30/09

Article

AMAG: FDA Delays Feraheme Decision

By Adam Feuerstein

AMAG says it expects the FDA to make its approval decision on iron replacement therapy Feraheme within a few days.

10:04AM 06/30/09

Article

Biotech Calendar: Key Clinical Trial Dates

By Adam Feuerstein

Part 3 in our quick-and-dirty guide to upcoming clinical trial dates for drug and biotech companies.

08:00AM 06/30/09

« Back
Page 1 of 382
Your Recent Quotes: Quote Up0 | Quote Down0
 
Dow S&P 500 NASDAQ
Oil*
65.43
8,280.74
896.42
1,796.52
10 Yr
3.50%
223.32
26.91
49.20
-2.63%
-2.91%
-2.67%
Data delayed 20 min
Get Jim Cramer's Free Newsletter

The Daily Booyah!
Get your daily dose of Cramer in your inbox.
Submit
We respect your privacy.

Brokerage Partners